Jeff Lagasse
One promising candidate is remdesivir, a drug originally developed for Ebola, which the FDA has approved for emergency use during the pandemic.
The test could detect COVID-19 infections in about six out of 10 people, and was nearly perfect in determining when an infection wasn't present.
By incorporating referrals into a physicians' EHR and creating a focused group of specialists, the shift to value is made that much easier.
Patient and staff morale has improved following implementation of a personalized, virtual rounding program intended to foster connectedness.
The experiment showed that improper removal of PPE can help facilitate the coronavirus' spread.
The results aim to act as a "playbook" of sorts for leaders and administrators who are looking for better ways to keep their group properly trained.
The general public experienced a similar arc, though it hasn't sunk as low as that of their healthcare counterparts since the pandemic took root.
Leveraging regulatory allowances and establishing sound analytic capabilities can help ensure patients continue treatment with necessary drugs.
Setting targets, focusing communication and getting buy-in from the entire organization will be necessary to succeed.
There's a crucial difference between patient satisfaction and patient loyalty, and understanding it can yield better retention.